Retatrutide for fatty liver looks promising in early research. In a 2024 phase 2 substudy, most people on the higher doses reached normal liver fat levels within a year. It's still investigational. TelosRX walks through the evidence.
Fatty liver is one of the most common liver problems in adults. It often has no symptoms until it's advanced. So when a weight-loss drug shows big liver fat drops in a trial, people pay attention.
Retatrutide is that drug right now. Below, we walk through what the published research on retatrutide for fatty liver actually found. Every finding is tied to a cited study. Nothing here is a promise of results.
Quick Background: Retatrutide and Fatty Liver
Retatrutide is an experimental once-weekly injection from Eli Lilly. It's a "triple agonist," meaning it activates three hormone receptors at once: GIP, GLP-1, and glucagon.
Fatty liver now goes by a new name: MASLD, short for metabolic dysfunction-associated steatotic liver disease. In plain English, it means too much fat stored in the liver, tied to things like excess weight, insulin resistance, and high triglycerides.
The glucagon piece is why liver researchers care. Glucagon signaling acts directly on the liver and is thought to increase fat burning there. GLP-1 drugs alone don't do that.
Important: retatrutide is not FDA-approved for any use. It's only available inside clinical trials.
How Retatrutide Might Act on the Liver
Researchers point to two likely routes. Both are still being studied.
- Indirect route: weight reduction. GLP-1 and GIP signaling reduce appetite and food intake. Less excess energy means less fat stored in the liver.
- Direct route: glucagon signaling. Glucagon receptors sit on liver cells. Activating them is thought to increase fat burning and reduce fat production inside the liver.
The rise in beta-hydroxybutyrate seen in the substudy fits the fat-burning idea. But a marker isn't proof of mechanism. That's why researchers still describe this as a hypothesis.
How to Read Liver Fat Numbers
Two kinds of numbers show up in liver studies. Mixing them up causes confusion.
- Relative reduction compares your liver fat to your own starting point. Going from 20% to 4% liver fat is an 80% relative reduction.
- Absolute liver fat is the share of the liver made of fat. Under 5% is the usual cutoff for normal.
The Key Studies at a Glance
Here's a summary of the main research. Each one is unpacked below.
| Study | Who was studied | Length | Main liver-related finding |
|---|---|---|---|
| Phase 2 obesity trial (NEJM, 2023) | 338 adults with obesity or overweight | 48 weeks | Large weight reduction; set the stage for the liver substudy |
| MASLD substudy (Nature Medicine, 2024) | 98 adults with obesity and ≥10% liver fat | 48 weeks | Liver fat fell up to 86% on average at the highest dose |
| Same substudy, metabolic markers | Same group | 48 weeks | Fasting insulin and triglycerides fell; adiponectin rose |
| Same substudy, safety | Same group | 48 weeks | Mostly mild-to-moderate GI effects; no liver toxicity signal |
| SYNERGY-Outcomes (phase 3) | Adults with MASLD | Ongoing | Recruiting; results not yet available |
Finding 1: The Obesity Trial That Started It
The liver story begins with a 48-week phase 2 trial of 338 adults. It was published in the New England Journal of Medicine in 2023.
At the 12 mg dose, the trial reported an average body weight reduction of 24.2% at 48 weeks. The placebo group averaged 2.1%.
Weight is closely tied to liver fat. So researchers built a liver substudy into the same trial to see what happened inside the liver.
Finding 2: Liver Fat Dropped Fast
The liver substudy was published in Nature Medicine in 2024 (Sanyal et al.). It enrolled 98 adults with obesity and at least 10% liver fat on MRI.
Liver fat was measured with MRI-PDFF, a scan that estimates the share of the liver made of fat. At 24 weeks, the average relative reductions were:
- Placebo: a 0.3% increase
- 1 mg: 42.9% reduction
- 4 mg: 57.0% reduction
- 8 mg: 81.4% reduction
- 12 mg: 82.4% reduction
Most of that change happened in the first six months. The effect was clearly dose-related.
Finding 3: Many Reached Normal Liver Fat
Below 5% liver fat is considered normal. At 24 weeks, 86% of people on 12 mg and 79% on 8 mg had dropped under that line. Nobody on placebo did.
By 48 weeks, the share reaching normal levels was 93% at 12 mg and 89% at 8 mg, per the substudy.
There's a catch. Only about 44% of participants had a 48-week MRI. So the 48-week numbers are less certain than the 24-week ones.
Finding 4: Weight Loss Explained Most of It
Liver fat reduction tracked closely with weight reduction. The correlation with body weight change was strong (r = 0.80 at 24 weeks).
The authors also noted that liver fat reduction was close to its maximum once weight reduction reached about 20%. Visceral fat, the fat packed around your organs, followed the same pattern.
In other words, the liver results appear to ride largely on weight reduction. Whether glucagon adds an extra liver-specific effect is still an open question.
Finding 5: Metabolic Markers Moved Too
The substudy measured several blood markers linked to fatty liver. At 48 weeks on the higher doses, it reported:
- Fasting insulin fell by up to about 71%, a sign of better insulin sensitivity.
- Triglycerides fell by more than 40% at 8 mg and 12 mg.
- Adiponectin, a fat-tissue hormone linked to metabolic health, rose.
- Beta-hydroxybutyrate, a marker of fat burning, rose two- to threefold.
Standard liver enzymes like ALT and AST didn't change consistently versus placebo. The authors noted most participants started with normal values, which leaves little room to drop.
Finding 6: Safety in the Liver Substudy
Side effects were mostly gastrointestinal. Nausea, diarrhea, and similar complaints were more common at 8 mg and 12 mg, mainly during dose increases.
Two participants had serious adverse events. One had acute gallbladder inflammation that required surgery. No signs of liver toxicity were seen through 48 weeks.
For a broader view of tolerability, see our breakdown of retatrutide side effects.
What This Research Doesn't Show
This is where honest reading matters. The authors themselves called the results "hypothesis-generating," not definitive. Key limits include:
- Small sample. Only 98 people, split across five groups.
- No liver biopsies. MRI shows fat, not inflammation or scarring.
- Narrow population. Mostly white US adults, without diabetes or advanced fibrosis.
- Industry-funded. Eli Lilly sponsored the trial.
- Missing data. Over half lacked a 48-week MRI.
Less liver fat is a good sign. But it isn't the same as proof of fewer liver complications over time. That needs larger, longer trials.
What Comes Next
Lilly's phase 3 TRIUMPH program is testing retatrutide for weight management. Topline results were announced in 2026, with full data still being published.
On the liver side, a phase 3 master protocol called SYNERGY-Outcomes is recruiting adults with MASLD. You can view it on ClinicalTrials.gov (NCT07165028).
Want the bigger picture on retatrutide trials? Our retatrutide clinical trial results guide covers the full program.
Options Available Today
Retatrutide isn't something you can get with a prescription today. If fatty liver and weight are on your radar, approved and established options exist.
GLP-1 medications like semaglutide and tirzepatide have their own liver research. We cover it in semaglutide and fatty liver disease.
Curious which GLP-1 options a provider might consider for you? Compare GLP-1 options at TelosRX. Any prescription is subject to medical approval by a licensed provider. Compounded GLP-1 medications are not FDA-approved.
TelosRX works asynchronously. You complete a secure online intake on your own time, and a licensed provider reviews it. No live appointment is needed.
Frequently Asked Questions
Does retatrutide reduce liver fat?
In a 2024 phase 2 substudy, retatrutide reduced liver fat substantially. At 24 weeks, average relative reductions were 81.4% at 8 mg and 82.4% at 12 mg, versus a slight increase on placebo. The study was small and industry-funded, so the results need confirmation in larger phase 3 trials before firm conclusions can be drawn.
Is retatrutide FDA-approved for fatty liver?
No. Retatrutide is not FDA-approved for fatty liver or any other use. It's an investigational drug available only through clinical trials. Lilly has said it plans to seek FDA approval for weight management. Any liver indication would require separate evidence, such as results from ongoing phase 3 studies in people with MASLD.
How long did it take retatrutide to lower liver fat?
Most of the liver fat reduction appeared by 24 weeks, the first major checkpoint in the substudy. At that point, 86% of people on 12 mg had normal liver fat below 5%. Results at 48 weeks were similar or slightly better, though fewer participants had a 48-week MRI scan.
Is the liver effect just from weight loss?
Mostly, based on current data. Liver fat reduction correlated strongly with weight reduction, and it neared its maximum at about 20% weight reduction. Retatrutide also activates the glucagon receptor, which acts on the liver. Whether that adds a liver-specific benefit beyond weight reduction hasn't been proven yet.
What is MASLD?
MASLD stands for metabolic dysfunction-associated steatotic liver disease. It's the newer name for what was called non-alcoholic fatty liver disease. It means excess fat in the liver linked to metabolic factors like excess weight, insulin resistance, high blood sugar, or high triglycerides. It often causes no symptoms early on.
Can I join a retatrutide liver trial?
Possibly. Phase 3 studies, including the SYNERGY-Outcomes master protocol, are recruiting adults with MASLD. Eligibility depends on factors like liver fat, other conditions, and location. You can search ClinicalTrials.gov and discuss it with your own clinician. Our guide on finding retatrutide trials explains the steps.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.